Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

The Effect of Deep Tissue Massage on Respiratory Parameters in People With Asthma

NCT06893445 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2025-07-01
Last updated
2025-03-25

Condition(s) studied

MassageAsthma Patients

Investigational drug(s) / intervention(s)

Deep Tissue MassageClassic massage

Deep Tissue Massage: Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.

Classic massage: The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.

Study summary

Bronchial asthma, as a chronic inflammatory disease of the respiratory tract, significantly reduces the quality of life of patients. Standard treatment includes pharmacotherapy, but a holistic approach, including manual therapies, can support pharmacological therapy, reducing the need for drugs.

The aim of the research is to verify whether deep tissue massage (DTM) techniques applied to the chest significantly affect respiratory parameters in people with asthma. The study is the next stage of the study conducted on healthy people. After obtaining positive results in the study involving people not suffering from respiratory diseases, the next step is to examine people with, in this case, bronchial asthma. It is important to determine whether the use of this form of manual therapy can bring benefits in the context of improving respiratory functions, reducing respiratory muscle tension and relieving subjective symptoms associated with asthma, such as shortness of breath or limitations in everyday functioning.

The hypothesis assumes that DTM techniques can have a bigger effect on the respiratory system than classic massage (CM).

The study is a randomized controlled trial, where participants will be randomly assigned to one of two groups: the study group (subjected to DTM) or the control group (subjected to CM). Before and after the massage intervention, participants will undergo spirometry to assess the changes in respiratory parameters. The obtained data will then be analyzed for effects on respiratory parameters and differences between both groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * diagnosed with bronchial asthma * stable health condition, allowing participation in the study * informed consent to participate in the study Exclusion Criteria: * acute or chronic comorbidities that may affect the results (e.g. COPD, heart failure, cancer) * any chest surgery performed within the last 6 months * contraindications to massage (e.g. skin infections, wounds) * pregnancy * participation in other clinical trials in the last 3 months

Primary outcome measure(s)

  • Assessment of change of lung vital capacity — twice: before and immediately after procedure administration in both groups
    The vital capacity of the lungs will be assessed with spirometer. The subject stood with legs hip-width apart. For each measurement, disposable cardboard mouthpieces will be used. The examined person holds the device vertically with both hands. At the examiner's command, subject will take in as much air as possible, then tightly biet the mouthpiece with his mouth, and with all of their strength, exhale air into the device for as long as possible. The subject will have only 1 attempt-measured values were recorded with an accuracy of 50 mL.
  • Assessment of change of chest circumference — twice: before and immediately after procedure administration in both groups
    The chest circumference will be measured with a measuring tape, wrapped horizontally around the chest at the level of the xiphoid process. The subject stand with feet hip-width apart, arms hanging along the body. At the command, the subject will take a maximum breathe in (first measurement) and exhale to the maximum for the next (second measurement). Obtained values will be recorded with an accuracy of 0.5 cm.
  • Assessment of change of blood oxygen saturation — twice: before and immediately after procedure administration in both groups
    Testing blood oxygen saturation will be performed in a sitting position with digital pulseoximeter. The device will be put on the second finger of the left hand each time. The highest value displayed by the pulseoximeter within 30 s will be recorded with an accuracy of 1%.
  • Asessment of change of Peak Expiratory Flow (PEF) — twice: before and immediately after procedure administration in both groups
    Dynamic spirometry test will be performed with spirometer to assess the peak expiratory flow (PEF) measured in liters per second \[l/s\]. The subject will sit with his legs on the floor-hip joint flexed at an angle of 70o-90o and carry out the following command: "Breathe calmly. On my command, breathe in as much as possible, as quickly as possible, as intensively as possible, and while at the top of the inhalation, without waiting, breathe out as hard and as long as possible ". This cycle will be performed at least 3 times obtaining 3 measurements and the mean value will be calculated.
  • Assessment of change of Forced Vital Capacity — twice: before and immediately after procedure administration in both groups
    The forced vital capacity (FVC), measured in liters will be assessed with spirometer. The subject will sit with his legs on the floor-hip joint flexed at an angle of 70o-90o and carry out the following command: "Breathe calmly. On my command, breathe in as much as possible, as quickly as possible, as intensively as possible, and while at the top of the inhalation, without waiting, breathe out as hard and as long as possible ".
  • Assessment of change of Maximum Expiratory Flow — twice: before and immediately after procedure administration in both groups
    Assessment of the maximum expiratory flow (MEF), measured in liters per second will be performed with spirometer. The subject will sit with his legs on the floor-hip joint flexed at an angle of 70o-90o and carry out the following command: "Breathe calmly. On my command, breathe in as much as possible, as quickly as possible, as intensively as possible, and while at the top of the inhalation, without waiting, breathe out as hard and as long as possible ". This cycle will be performed at least 3 times obtaining 3 measurements and the mean value will be calculated.
  • Assessment of change of Forced Expiratory Volume in one second — twice: before and immediately after procedure administration in both groups
    Assessment of the forced expiratory volume in 1 s (FEV1) measured in literswill be performed with spirometer. The subject will sit with his legs on the floor-hip joint flexed at an angle of 70o-90o and carry out the following command: "Breathe calmly. On my command, breathe in as much as possible, as quickly as possible, as intensively as possible, and while at the top of the inhalation, without waiting, breathe out as hard and as long as possible ". This cycle will be performed at least 3 times obtaining 3 measurements and the mean value will be calculated.
  • Assessment of change of Maximum Voluntary Ventilation — twice: before and immediately after procedure administration in both groups
    Assessing the maximum voluntary ventilation (MVV) measured in liters per minute will be performed with spirometer. The subject will sit with his legs on the floor-hip joint flexed at an angle of 70o-90o and carried out the following command: "Breathe calmly. On my command, inhale and exhale as quickly and as deeply as possible for 15 s until you hear the 'stop' command. This cycle will be performed at least 3 times obtaining 3 measurements and the mean value will be calculated.

Trial sites (2)

FacilityCityRegionStatus
Department of Physiotherapy, Faculty of Health Sciences, Jagiellonian University Medical College Cracow Poland
The "Wieliczka" Salt Mine Health Resort Wieliczka Poland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06893445 on ClinicalTrials.gov ↗ ← All trials in Poland